19 results on '"Kuhlmann, Tine Plato"'
Search Results
2. Prediction of disease recurrence or residual disease after primary endoscopic resection of pT1 colorectal cancer—results from a large nationwide Danish study
- Author
-
Ose, Ilze, Levic, Katarina, Thygesen, Lau Caspar, Bulut, Orhan, Bisgaard, Thue, Gögenur, Ismail, and Kuhlmann, Tine Plato
- Published
- 2023
- Full Text
- View/download PDF
3. Risk of Cancer and Mortality in Peutz-Jeghers Syndrome and Juvenile Polyposis Syndrome—A Nationwide Cohort Study With Matched Controls
- Author
-
Jelsig, Anne Marie, Wullum, Laus, Kuhlmann, Tine Plato, Ousager, Lilian Bomme, Burisch, Johan, and Karstensen, John Gásdal
- Published
- 2023
- Full Text
- View/download PDF
4. Endoscopic indicators in patients with familial adenomatous polyposis undergoing duodenal resections – a nationwide Danish cohort study with long-term follow-up
- Author
-
Karstensen, John Gásdal, primary, Wewer, Mads, additional, Bülow, Steffen, additional, Hansen, Thmas Van Overreem, additional, Højen, Helle, additional, Jelsig, Anne Marie, additional, Kuhlmann, Tine Plato, additional, Burisch, Johan, additional, and Pommergaard, Hans Christian, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Completion total mesorectal excision following transanal endoscopic microsurgery does not compromise outcomes in patients with rectal cancer
- Author
-
Levic Souzani, Katarina, Bulut, Orhan, Kuhlmann, Tine Plato, Gögenur, Ismail, and Bisgaard, Thue
- Published
- 2022
- Full Text
- View/download PDF
6. Incidents in Molecular Pathology: Frequency and Causes During Routine Testing
- Author
-
Keppens, Cleo, Van Royen, Yann, Brysse, Anne, Cotteret, Sophie, Hogdall, Estrid, Kuhlmann, Tine Plato, OSullivan, Brendan, Pauwels, Patrick, Pauwels, Siegrid, Rot, Mitja, Vanderheyden, Nancy, Van Hee, Ilse, and Dequeker, Elisabeth M.C.
- Subjects
Diagnostic errors -- Statistics -- Causes of ,Pathology, Molecular -- Statistics ,Diagnosis, Laboratory -- Statistics ,Health - Abstract
* Context.--Errors in laboratory medicine could compromise patient safety. Good laboratory practice includes identifying and managing nonconformities in the total test process. Varying error percentages have been described in other fields but are lacking for molecular oncology. Objectives.--To gain insight into incident causes and frequency in the total test process from 8 European institutes routinely performing biomarker tests in non-small cell lung cancer and colorectal cancer. Design.--All incidents documented in 2018 were collected from all hospital services for pre-preanalytical entries before the biomarker test, as well as specific incidents for biomarker tests. Results.--There were 5185 incidents collected, of which 4363 (84.1%) occurred in the pre-preanalytical phase (all hospital services), 2796 of 4363 (64.1%) related to missing or incorrect request form information. From the other 822 specific incidents, 166 (20.2%) were recorded in the preanalytical phase, 275 (33.5%) in the analytical phase, and 194 (23.6%) in the postanalytical phase, mainly due to incorrect report content. Only 47 of 822 (5.7%) incidents were recorded in the post-postanalytical phase, and 123 (15.0%) in the complete total test process. For 17 of 822 (2.1%) incidents the time point was unknown. Pre-pre-analytical incidents were resolved sooner than incidents on the complete process (mean 6 versus 60 days). For 1215 of 5168 (23.5%) incidents with known causes a specific action was undertaken besides documenting them, not limited to accredited institutes. Conclusions.--There was a large variety in the number and extent of documented incidents. Correct and complete information on the request forms and final reports are highly error prone and require additional focus. doi: 10.5858/arpa.2020-0152-OA, Errors in laboratory medicine could significantly compromise patient safety. According to the International Organization for Standardization (ISO) technical specification ISO/TS 22367:2008, all clinical laboratories must (1) implement measures to detect [...]
- Published
- 2021
- Full Text
- View/download PDF
7. Colorectal serrated lesions and polyps in the Danish population: A large nationwide register-based cohort study
- Author
-
Andrea, Mille, additional, Jepsen, Rikke Karlin, additional, Klein, Mads Falk, additional, Gögenur, Ismail, additional, and Kuhlmann, Tine Plato, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Temporal trends and regional variability in BRAF and KRAS genetic testing in Denmark (2010–2022): Implications for precision medicine.
- Author
-
Frost, Matilde Grupe, Jensen, Kristoffer Jarlov, Jimenez‐Solem, Espen, Qvortrup, Camilla, Kuhlmann, Tine Plato, Andersen, Jon Lykkegaard, Høgdall, Estrid, and Petersen, Tonny Studsgaard
- Published
- 2024
- Full Text
- View/download PDF
9. Cancer risk and mortality in patients with solitary juvenile polyps — A nationwide cohort study with matched controls
- Author
-
Jelsig, Anne Marie, Wullum, Laus, Kuhlmann, Tine Plato, Ousager, Lilian Bomme, Burisch, Johan, Karstensen, John Gásdal, Jelsig, Anne Marie, Wullum, Laus, Kuhlmann, Tine Plato, Ousager, Lilian Bomme, Burisch, Johan, and Karstensen, John Gásdal
- Abstract
Introduction: The risk of cancer in patients with solitary colorectal juvenile polyps (JPs) is poorly investigated and several studies have reported polyps with dysplastic and adenomatous alterations. We aimed to investigate the long-term risk of cancer and mortality in these patients by merging data from national registers and comparing them to a matched control cohort. Materials and Methods: Patients with a solitary JP were identified in The Danish National Pathology Register and Data Bank (DNPR). The included patients were matched on sex, age, and place of birth with 50 controls. The groups were then analyzed for risk of cancer using the Danish Cancer Registry and mortality using the Danish Cause of Death Registry. Results: We identified 1781 patients with solitary JPs and matched them with 83,713 controls. The mean follow-up time was 7.65 years for cases and 7.36 years for controls. The risk of cancer, including colorectal cancer, did not differ for the two groups and when adjusting for sex and year of birth, the hazard ratio (HR) was 1.15 (confidence interval [CI] 95% 0.94–1.41, p = 0.162). There was no increased risk of death (HR: 1.07, CI 95% 0.88–1.30, p = 0.486). The risk did not differ for different age groups or sex. Conclusion: There is no increased risk of cancer or mortality for patients with solitary colorectal JPs. Thus, endoscopic follow-up may be safely omitted in these patients.
- Published
- 2023
10. Colorectal serrated lesions and polyps in the Danish population:A large nationwide register-based cohort study
- Author
-
Andrea, Mille, Jepsen, Rikke Karlin, Klein, Mads Falk, Gögenur, Ismail, Kuhlmann, Tine Plato, Andrea, Mille, Jepsen, Rikke Karlin, Klein, Mads Falk, Gögenur, Ismail, and Kuhlmann, Tine Plato
- Abstract
ackground and study aims Colorectal serrated lesions and polyps (SPs) include hyperplastic polyps (HP), sessile serrated lesions-/+dysplasia (SSL/SSL-D), and traditional serrated adenomas (TSA). From 20% to 30% of colorectal cancers (CRC) develop from SP. We present incidence and baseline characteristics of SP in a Danish cohort. Patients and methods We used The Danish Pathology Registry to include all SPs in the Danish population from January 1, 2000 to December 31, 2021. Based on the unique Danish personal identification number and SNOMED-codes, combined with the age and sex of patients, and date of procedure, we determined the incidence of the SP subtypes, anatomical location, and changes over time. Results During the period from 2000 to 2021, a total of 292,761 SPs were removed from 163,840 patients: 51,649 SSLs, 5959 SSL-Ds, 224,860 HDs, and 10,293 TSAs. The median age of patients was 64.1 years (range 55.2–71.6) and 53.3% were male. We found a general increase in SPs from 3525 in 2000 to 25,853 in 2021 and a rise in the SSL proportion from 1.7% in 2006 to 38% in 2021. Half of all patients had more than one lesion at endoscopy with conventional adenomas being the most common. CRC was found along with SPs in 3.3% of procedures, while 1% to 2.5% of the patients developed metachronous CRC. Conclusions We found an increasing number of SPs, especially SSLs. From 2019 to 2021 the number of SPs seem to stabilize, while the proportion of SSLs keeps rising. Synchronous lesions were common along all subtypes of SP. Keywords Colorectal cancer - CRC screening - GI Pathology - Epidemiology, Background and study aims Colorectal serrated lesions and polyps (SPs) include hyperplastic polyps (HP), sessile serrated lesions-/+dysplasia (SSL/SSL-D), and traditional serrated adenomas (TSA). From 20% to 30% of colorectal cancers (CRC) develop from SP. We present incidence and baseline characteristics of SP in a Danish cohort. Patients and methods We used The Danish Pathology Registry to include all SPs in the Danish population from January 1, 2000 to December 31, 2021. Based on the unique Danish personal identification number and SNOMED-codes, combined with the age and sex of patients, and date of procedure, we determined the incidence of the SP subtypes, anatomical location, and changes over time. Results During the period from 2000 to 2021, a total of 292,761 SPs were removed from 163,840 patients: 51,649 SSLs, 5959 SSL-Ds, 224,860 HDs, and 10,293 TSAs. The median age of patients was 64.1 years (range 55.2-71.6) and 53.3% were male. We found a general increase in SPs from 3525 in 2000 to 25,853 in 2021 and a rise in the SSL proportion from 1.7% in 2006 to 38% in 2021. Half of all patients had more than one lesion at endoscopy with conventional adenomas being the most common. CRC was found along with SPs in 3.3% of procedures, while 1% to 2.5% of the patients developed metachronous CRC. Conclusions We found an increasing number of SPs, especially SSLs. From 2019 to 2021 the number of SPs seem to stabilize, while the proportion of SSLs keeps rising. Synchronous lesions were common along all subtypes of SP.
- Published
- 2023
11. Novel Genetic Causes of Gastrointestinal Polyposis Syndromes
- Author
-
Jelsig,Anne Marie, Byrjalsen,Anna, Busk Madsen,Majbritt, Kuhlmann,Tine Plato, van Overeem Hansen,Thomas, Wadt,Karin AW, and Karstensen,John Gásdal
- Subjects
The Application of Clinical Genetics ,human activities ,humanities - Abstract
Anne Marie Jelsig,1 Anna Byrjalsen,1 Majbritt Busk Madsen,2 Tine Plato Kuhlmann,3 Thomas van Overeem Hansen,1 Karin AW Wadt,1,4 John Gásdal Karstensen4,5 1Department of Clinical Genetics, University Hospital of Copenhagen, Copenhagen, Denmark; 2Center for Genomic Medicine, University Hospital of Copenhagen, Copenhagen, Denmark; 3Department of Pathology, University Hospital of Copenhagen, Herlev Hospital, Herlev, Denmark; 4Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; 5Danish Polyposis Registry, Gastro Unit, Copenhagen University Hospital â Amager and Hvidovre, Copenhagen, DenmarkCorrespondence: Anne Marie JelsigDepartment of Clinical Genetics, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, DenmarkTel +45 20 36 18 85Email anne.marie.jelsig@regionh.dkAbstract: Hereditary polyposis syndromes are characterized by a large number and/or histopathologically specific polyps in the gastrointestinal tract and a high risk of both colorectal cancer and extracolonic cancer at an early age. While the genes responsible for some of the syndromes, eg, APC in familial adenomatous polyposis and STK11 in Peutz-Jeghers syndrome, have been known for decades, novel genetic causes have recently been detected that have shed light on the broader clinical spectrum of syndromes. Genetic diagnoses are important because they can facilitate a personalized surveillance program. Furthermore, at-risk members of the patientâs family can be tested and enrolled in surveillance as needed. In some cases, prenatal diagnostics should be offered. In this paper, we describe the development in germline genetics of the hereditary polyposis syndromes over the last 10â 12 years, their clinical characteristics, as well as how to implement genetic analyses in the diagnostic pipeline.Keywords: polyposis, hereditary, familial adenomatous polyposis, cancer, management
- Published
- 2021
12. Improving tumor budding reporting in colorectal cancer: a Delphi consensus study
- Author
-
Haddad, Tariq Sami, Lugli, Alessandro, Aherne, Susan, Barresi, Valeria, Terris, Benoit, Bokhorst, John-Melle, Brockmoeller, Scarlet Fiona, Cuatrecasas, Miriam, Simmer, Femke, El-Zimaity, Hala, Flejou, Jean-Francois, Gibbons, David, Cathomas, Gieri, Kirsch, Richard, Kuhlmann, Tine Plato, Langner, Cord, Loughrey, Maurice B., Riddell, Robert, Ristimaki, Ari, Kakar, Sanjay, Sheahan, Kieran, Treanor, Darren, van der Laak, Jeroen, Vieth, Michael, Zlobec, Inti, Nagtegaal, Iris D., Haddad, Tariq Sami, Lugli, Alessandro, Aherne, Susan, Barresi, Valeria, Terris, Benoit, Bokhorst, John-Melle, Brockmoeller, Scarlet Fiona, Cuatrecasas, Miriam, Simmer, Femke, El-Zimaity, Hala, Flejou, Jean-Francois, Gibbons, David, Cathomas, Gieri, Kirsch, Richard, Kuhlmann, Tine Plato, Langner, Cord, Loughrey, Maurice B., Riddell, Robert, Ristimaki, Ari, Kakar, Sanjay, Sheahan, Kieran, Treanor, Darren, van der Laak, Jeroen, Vieth, Michael, Zlobec, Inti, and Nagtegaal, Iris D.
- Abstract
Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet methods for its assessment have varied widely. In an effort to standardize its reporting, a group of experts met in Bern, Switzerland, in 2016 to reach consensus on a single, international, evidence-based method for tumor budding assessment and reporting (International Tumor Budding Consensus Conference [ITBCC]). Tumor budding assessment using the ITBCC criteria has been validated in large cohorts of cancer patients and incorporated into several international colorectal cancer pathology and clinical guidelines. With the wider reporting of tumor budding, new issues have emerged that require further clarification. To better inform researchers and health-care professionals on these issues, an international group of experts in gastrointestinal pathology participated in a modified Delphi process to generate consensus and highlight areas requiring further research. This effort serves to re-affirm the importance of tumor budding in colorectal cancer and support its continued use in routine clinical practice., Funding Agencies|Dutch Cancer SocietyKWF Kankerbestrijding [10602/2016-2]
- Published
- 2021
- Full Text
- View/download PDF
13. Novel Genetic Causes of Gastrointestinal Polyposis Syndromes
- Author
-
Jelsig, Anne Marie, Byrjalsen, Anna, Madsen, Majbritt Busk, Kuhlmann, Tine Plato, Hansen, Thomas van Overeem, Wadt, Karin A.W., Karstensen, John Gásdal, Jelsig, Anne Marie, Byrjalsen, Anna, Madsen, Majbritt Busk, Kuhlmann, Tine Plato, Hansen, Thomas van Overeem, Wadt, Karin A.W., and Karstensen, John Gásdal
- Abstract
Hereditary polyposis syndromes are characterized by a large number and/or histopathologically specific polyps in the gastrointestinal tract and a high risk of both colorectal cancer and extracolonic cancer at an early age. While the genes responsible for some of the syndromes, eg, APC in familial adenomatous polyposis and STK11 in Peutz-Jeghers syndrome, have been known for decades, novel genetic causes have recently been detected that have shed light on the broader clinical spectrum of syndromes. Genetic diagnoses are important because they can facilitate a personalized surveillance program. Furthermore, at-risk members of the patient’s family can be tested and enrolled in surveillance as needed. In some cases, prenatal diagnostics should be offered. In this paper, we describe the development in germline genetics of the hereditary polyposis syndromes over the last 10–12 years, their clinical characteristics, as well as how to implement genetic analyses in the diagnostic pipeline.
- Published
- 2021
14. Improving tumor budding reporting in colorectal cancer:a Delphi consensus study
- Author
-
Haddad, Tariq Sami, Lugli, Alessandro, Aherne, Susan, Barresi, Valeria, Terris, Benoît, Bokhorst, John Melle, Brockmoeller, Scarlet Fiona, Cuatrecasas, Miriam, Simmer, Femke, El-Zimaity, Hala, Fléjou, Jean François, Gibbons, David, Cathomas, Gieri, Kirsch, Richard, Kuhlmann, Tine Plato, Langner, Cord, Loughrey, Maurice B., Riddell, Robert, Ristimäki, Ari, Kakar, Sanjay, Sheahan, Kieran, Treanor, Darren, van der Laak, Jeroen, Vieth, Michael, Zlobec, Inti, Nagtegaal, Iris D., Haddad, Tariq Sami, Lugli, Alessandro, Aherne, Susan, Barresi, Valeria, Terris, Benoît, Bokhorst, John Melle, Brockmoeller, Scarlet Fiona, Cuatrecasas, Miriam, Simmer, Femke, El-Zimaity, Hala, Fléjou, Jean François, Gibbons, David, Cathomas, Gieri, Kirsch, Richard, Kuhlmann, Tine Plato, Langner, Cord, Loughrey, Maurice B., Riddell, Robert, Ristimäki, Ari, Kakar, Sanjay, Sheahan, Kieran, Treanor, Darren, van der Laak, Jeroen, Vieth, Michael, Zlobec, Inti, and Nagtegaal, Iris D.
- Abstract
Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet methods for its assessment have varied widely. In an effort to standardize its reporting, a group of experts met in Bern, Switzerland, in 2016 to reach consensus on a single, international, evidence-based method for tumor budding assessment and reporting (International Tumor Budding Consensus Conference [ITBCC]). Tumor budding assessment using the ITBCC criteria has been validated in large cohorts of cancer patients and incorporated into several international colorectal cancer pathology and clinical guidelines. With the wider reporting of tumor budding, new issues have emerged that require further clarification. To better inform researchers and health-care professionals on these issues, an international group of experts in gastrointestinal pathology participated in a modified Delphi process to generate consensus and highlight areas requiring further research. This effort serves to re-affirm the importance of tumor budding in colorectal cancer and support its continued use in routine clinical practice.
- Published
- 2021
15. Incidents in molecular pathology:Frequency and causes during routine testing
- Author
-
Keppens, Cleo, van Royen, Yann, Brysse, Anne, Cotteret, Sophie, Høgdall, Estrid, Kuhlmann, Tine Plato, O'Sullivan, Brendan, Pauwels, Patrick, Pauwels, Siegrid, Rot, Mitja, Vanderheyden, Nancy, van Hee, Ilse, Dequeker, Elisabeth M.C., Keppens, Cleo, van Royen, Yann, Brysse, Anne, Cotteret, Sophie, Høgdall, Estrid, Kuhlmann, Tine Plato, O'Sullivan, Brendan, Pauwels, Patrick, Pauwels, Siegrid, Rot, Mitja, Vanderheyden, Nancy, van Hee, Ilse, and Dequeker, Elisabeth M.C.
- Abstract
Context.-Errors in laboratory medicine could compromise patient safety. Good laboratory practice includes identifying and managing nonconformities in the total test process. Varying error percentages have been described in other fields but are lacking for molecular oncology. Objectives.-To gain insight into incident causes and frequency in the total test process from 8 European institutes routinely performing biomarker tests in non-small cell lung cancer and colorectal cancer. Design.-All incidents documented in 2018 were collected from all hospital services for pre-preanalytical entries before the biomarker test, as well as specific incidents for biomarker tests. Results.-There were 5185 incidents collected, of which 4363 (84.1%) occurred in the pre-preanalytical phase (all hospital services), 2796 of 4363 (64.1%) related to missing or incorrect request form information. From the other 822 specific incidents, 166 (20.2%) were recorded in the preanalytical phase, 275 (33.5%) in the analytical phase, and 194 (23.6%) in the postanalytical phase, mainly due to incorrect report content. Only 47 of 822 (5.7%) incidents were recorded in the post-postanalytical phase, and 123 (15.0%) in the complete total test process. For 17 of 822 (2.1%) incidents the time point was unknown. Pre-preanalytical incidents were resolved sooner than incidents on the complete process (mean 6 versus 60 days). For 1215 of 5168 (23.5%) incidents with known causes a specific action was undertaken besides documenting them, not limited to accredited institutes. Conclusions.-There was a large variety in the number and extent of documented incidents. Correct and complete information on the request forms and final reports are highly error prone and require additional focus.
- Published
- 2021
16. Improving tumor budding reporting in colorectal cancer: a Delphi consensus study
- Author
-
Haddad, Tariq Sami, primary, Lugli, Alessandro, additional, Aherne, Susan, additional, Barresi, Valeria, additional, Terris, Benoît, additional, Bokhorst, John-Melle, additional, Brockmoeller, Scarlet Fiona, additional, Cuatrecasas, Miriam, additional, Simmer, Femke, additional, El-Zimaity, Hala, additional, Fléjou, Jean-François, additional, Gibbons, David, additional, Cathomas, Gieri, additional, Kirsch, Richard, additional, Kuhlmann, Tine Plato, additional, Langner, Cord, additional, Loughrey, Maurice B., additional, Riddell, Robert, additional, Ristimäki, Ari, additional, Kakar, Sanjay, additional, Sheahan, Kieran, additional, Treanor, Darren, additional, van der Laak, Jeroen, additional, Vieth, Michael, additional, Zlobec, Inti, additional, and Nagtegaal, Iris D., additional
- Published
- 2021
- Full Text
- View/download PDF
17. Completion total mesorectal excision following transanal endoscopic microsurgery does not compromise outcomes in patients with rectal cancer
- Author
-
Levic Souzani, Katarina, primary, Bulut, Orhan, additional, Kuhlmann, Tine Plato, additional, Gögenur, Ismail, additional, and Bisgaard, Thue, additional
- Published
- 2021
- Full Text
- View/download PDF
18. Kuhlmann, Tine Plato
- Author
-
Kuhlmann, Tine Plato and Kuhlmann, Tine Plato
- Published
- 2014
19. Cancer risk and mortality in patients with solitary juvenile polyps-A nationwide cohort study with matched controls.
- Author
-
Jelsig AM, Wullum L, Kuhlmann TP, Ousager LB, Burisch J, and Karstensen JG
- Subjects
- Humans, Cohort Studies, Intestinal Polyps, Intestinal Polyposis pathology, Adenoma pathology, Colorectal Neoplasms epidemiology, Colorectal Neoplasms pathology
- Abstract
Introduction: The risk of cancer in patients with solitary colorectal juvenile polyps (JPs) is poorly investigated and several studies have reported polyps with dysplastic and adenomatous alterations. We aimed to investigate the long-term risk of cancer and mortality in these patients by merging data from national registers and comparing them to a matched control cohort., Materials and Methods: Patients with a solitary JP were identified in The Danish National Pathology Register and Data Bank (DNPR). The included patients were matched on sex, age, and place of birth with 50 controls. The groups were then analyzed for risk of cancer using the Danish Cancer Registry and mortality using the Danish Cause of Death Registry., Results: We identified 1781 patients with solitary JPs and matched them with 83,713 controls. The mean follow-up time was 7.65 years for cases and 7.36 years for controls. The risk of cancer, including colorectal cancer, did not differ for the two groups and when adjusting for sex and year of birth, the hazard ratio (HR) was 1.15 (confidence interval [CI] 95% 0.94-1.41, p = 0.162). There was no increased risk of death (HR: 1.07, CI 95% 0.88-1.30, p = 0.486). The risk did not differ for different age groups or sex., Conclusion: There is no increased risk of cancer or mortality for patients with solitary colorectal JPs. Thus, endoscopic follow-up may be safely omitted in these patients., (© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.